Cargando…
The prognostic value of quality of life in atrial fibrillation on patient value
BACKGROUND: In this study, the prognostic value of AF-related quality of life (AFEQT) at baseline on Major Adverse Cardiovascular Events (MACE) and improvement of perceived symptoms (EHRA) was assessed. Furthermore, the relationship between QoL and AF-related hospitalizations was assessed. METHODS:...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074786/ https://www.ncbi.nlm.nih.gov/pubmed/37016364 http://dx.doi.org/10.1186/s12955-023-02112-2 |
_version_ | 1785019810531246080 |
---|---|
author | Theunissen, Luc J.H.J. van de Pol, Jeroen A.A. van Steenbergen, Gijs J. Cremers, Henricus-Paul van Veghel, Dennis van der Voort, Pepijn H. Polak, Peter E. de Jong, Sylvie F.A.M.S. Seelig, Jaap Smits, Geert Kemps, Hareld M.C. Dekker, Lukas R.C. |
author_facet | Theunissen, Luc J.H.J. van de Pol, Jeroen A.A. van Steenbergen, Gijs J. Cremers, Henricus-Paul van Veghel, Dennis van der Voort, Pepijn H. Polak, Peter E. de Jong, Sylvie F.A.M.S. Seelig, Jaap Smits, Geert Kemps, Hareld M.C. Dekker, Lukas R.C. |
author_sort | Theunissen, Luc J.H.J. |
collection | PubMed |
description | BACKGROUND: In this study, the prognostic value of AF-related quality of life (AFEQT) at baseline on Major Adverse Cardiovascular Events (MACE) and improvement of perceived symptoms (EHRA) was assessed. Furthermore, the relationship between QoL and AF-related hospitalizations was assessed. METHODS: A cohort of AF-patients diagnosed between November 2014 and October 2019 in four hospitals embedded within the Netherlands Heart Network were prospectively followed for 12 months. MACE was defined as stroke, myocardial infarction, heart failure and/or mortality. Subsequently, MACE, EHRA score improvement and AF-related hospitalizations between baseline and 12 months of follow-up were recorded. RESULTS: In total, 970 AF-patients were available for analysis. In analyses with patients with complete information on the confounder subset 36/687 (5.2%) AF-patients developed MACE, 190/432 (44.0%) improved in EHRA score and 189/510(37.1%) were hospitalized during 12 months of follow-up. Patients with a low AFEQT score at baseline more often developed MACE (OR(95%CI): 2.42(1.16–5.06)), more often improved in EHRA score (OR(95%CI): 4.55(2.45–8.44) and were more often hospitalized (OR(95%CI): 4.04(2.22–7.01)) during 12 months post diagnosis, compared to patients with a high AFEQT score at baseline. CONCLUSIONS: AF-patients with a lower quality of life at diagnosis more often develop MACE, more often improve on their symptoms and also were more often hospitalized, compared to AF-patients with a higher quality of life. This study highlights that the integration of patient-reported outcomes, such as quality of life, has the potential to be used as a prognostic indicator of the expected disease course for AF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-023-02112-2. |
format | Online Article Text |
id | pubmed-10074786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100747862023-04-06 The prognostic value of quality of life in atrial fibrillation on patient value Theunissen, Luc J.H.J. van de Pol, Jeroen A.A. van Steenbergen, Gijs J. Cremers, Henricus-Paul van Veghel, Dennis van der Voort, Pepijn H. Polak, Peter E. de Jong, Sylvie F.A.M.S. Seelig, Jaap Smits, Geert Kemps, Hareld M.C. Dekker, Lukas R.C. Health Qual Life Outcomes Research BACKGROUND: In this study, the prognostic value of AF-related quality of life (AFEQT) at baseline on Major Adverse Cardiovascular Events (MACE) and improvement of perceived symptoms (EHRA) was assessed. Furthermore, the relationship between QoL and AF-related hospitalizations was assessed. METHODS: A cohort of AF-patients diagnosed between November 2014 and October 2019 in four hospitals embedded within the Netherlands Heart Network were prospectively followed for 12 months. MACE was defined as stroke, myocardial infarction, heart failure and/or mortality. Subsequently, MACE, EHRA score improvement and AF-related hospitalizations between baseline and 12 months of follow-up were recorded. RESULTS: In total, 970 AF-patients were available for analysis. In analyses with patients with complete information on the confounder subset 36/687 (5.2%) AF-patients developed MACE, 190/432 (44.0%) improved in EHRA score and 189/510(37.1%) were hospitalized during 12 months of follow-up. Patients with a low AFEQT score at baseline more often developed MACE (OR(95%CI): 2.42(1.16–5.06)), more often improved in EHRA score (OR(95%CI): 4.55(2.45–8.44) and were more often hospitalized (OR(95%CI): 4.04(2.22–7.01)) during 12 months post diagnosis, compared to patients with a high AFEQT score at baseline. CONCLUSIONS: AF-patients with a lower quality of life at diagnosis more often develop MACE, more often improve on their symptoms and also were more often hospitalized, compared to AF-patients with a higher quality of life. This study highlights that the integration of patient-reported outcomes, such as quality of life, has the potential to be used as a prognostic indicator of the expected disease course for AF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-023-02112-2. BioMed Central 2023-04-05 /pmc/articles/PMC10074786/ /pubmed/37016364 http://dx.doi.org/10.1186/s12955-023-02112-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Theunissen, Luc J.H.J. van de Pol, Jeroen A.A. van Steenbergen, Gijs J. Cremers, Henricus-Paul van Veghel, Dennis van der Voort, Pepijn H. Polak, Peter E. de Jong, Sylvie F.A.M.S. Seelig, Jaap Smits, Geert Kemps, Hareld M.C. Dekker, Lukas R.C. The prognostic value of quality of life in atrial fibrillation on patient value |
title | The prognostic value of quality of life in atrial fibrillation on patient value |
title_full | The prognostic value of quality of life in atrial fibrillation on patient value |
title_fullStr | The prognostic value of quality of life in atrial fibrillation on patient value |
title_full_unstemmed | The prognostic value of quality of life in atrial fibrillation on patient value |
title_short | The prognostic value of quality of life in atrial fibrillation on patient value |
title_sort | prognostic value of quality of life in atrial fibrillation on patient value |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074786/ https://www.ncbi.nlm.nih.gov/pubmed/37016364 http://dx.doi.org/10.1186/s12955-023-02112-2 |
work_keys_str_mv | AT theunissenlucjhj theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vandepoljeroenaa theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vansteenbergengijsj theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT cremershenricuspaul theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vanvegheldennis theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vandervoortpepijnh theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT polakpetere theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT dejongsylviefams theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT seeligjaap theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT smitsgeert theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT kempshareldmc theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT dekkerlukasrc theprognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT theunissenlucjhj prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vandepoljeroenaa prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vansteenbergengijsj prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT cremershenricuspaul prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vanvegheldennis prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT vandervoortpepijnh prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT polakpetere prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT dejongsylviefams prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT seeligjaap prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT smitsgeert prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT kempshareldmc prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue AT dekkerlukasrc prognosticvalueofqualityoflifeinatrialfibrillationonpatientvalue |